Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
DENV NS2B-NS3 protease inhibitor
ZINC03129319 is a dengue virus (DENV) NS2B-NS3 protease inhibitor extracted from patent US20150141521A1, has inhibition constants (Ki1) of 92±15 μM and Ki3 of 20±4 μM. -
DENV Polymerase Inhibitor
NITD-2 is a selective inhibitor of dengue virus (DENV) polymerase, specifically targeting the RNA-dependent RNA polymerase (RdRp) to impede RNA elongation. This compound exhibits potent antiviral activity against DENV, making it a valuable tool for research focused on understanding dengue virus replication and developing therapeutic strategies. Its limited ability to penetrate cell membranes can be an important consideration for in vitro experimental design. -
Dengue Virus Protease Inhibitor
SP-471P is a potent inhibitor of the dengue virus (DENV) protease, exhibiting EC50 values of 5.9 μM, 1.4 μM, 5.1 μM, and 1.7 μM against DENV1, DENV2, DENV3, and DENV4, respectively, with a CC50 exceeding 100 μM. This compound effectively reduces DENV viral RNA synthesis, making it a valuable tool for research in dengue virus biology and antiviral therapeutic development. -
DENV Inhibitor
DENV-IN-4 is a potent inhibitor of Dengue Virus (DENV), exhibiting an EC50 value of 4.79 µM in Vero cells with a selectivity index greater than 20.9. This compound effectively reduces the expression levels of DENV2 in a concentration-dependent manner and inhibits RNA-dependent RNA polymerase (RdRp) enzymatic activity. DENV-IN-4 is valuable for research applications focused on understanding DENV pathogenesis and developing antiviral therapies. -
DENV/ZIKV Inhibitor
Antiviral agent 36 is a potent inhibitor of dengue virus (DENV) and Zika virus (ZIKV), demonstrating effective antiviral activity. It inhibits viral replication with EC50 values of 100 nM for ZIKV-FLR, 90 nM for ZIKV-HN16, 210 nM for DENV-2, and 120 nM for DENV-3. This compound serves as a valuable tool for research focused on the therapeutic development and understanding of DENV and ZIKV infections. -
DENV Inhibitor
DENV-IN-7 is a flavone analog that functions as a dengue virus (DENV) inhibitor, demonstrating an EC50 value of 70 nM. This compound exhibits low toxicity to normal cells while maintaining effective antiviral activity against DENV. It is suitable for research applications focused on the development of therapeutics for dengue virus infections. -
Dengue Viral Replication Inhibitor
DENV-IN-2 is a potent inhibitor of dengue viral replication, demonstrating exceptional activity against all four serotypes of the dengue virus. With an EC50 ranging from 0.013 to 0.029 nM, it shows remarkable efficacy in suppressing viral activity. This compound is valuable for research applications targeting dengue virus pathogenesis and developing antiviral strategies. -
DENV Inhibitor
DENV-IN-6 is a powerful inhibitor of dengue virus (DENV) serotypes I-IV, exhibiting effective antiviral activity with EC50 values of 17.5, 13.20, 6.8, and 11.41 μM, respectively, for the inhibition of viral replication. Additionally, DENV-IN-6 demonstrates notable activity against HIV-1 IIIB, with an EC50 of 0.0181 µM and a cytotoxicity (CC50) of 64.92 µM. This compound serves as a valuable tool for research into antiviral therapies targeting DENV and HIV-1. -
DENV/HIV-1 Inhibitor
DENV-IN-5 is a potent inhibitor targeting both dengue virus (DENV) and HIV-1 replication. It demonstrates effective antiviral activity with half-maximal effective concentration (EC50) values of 1.47, 9.23, 7.08, and 8.91 μM against DENV serotypes I to IV, respectively. Additionally, DENV-IN-5 inhibits the HIV-1 IIIB strain with an EC50 of 0.1512 μM. This compound is valuable for research focused on viral infections and the development of antiviral therapies. -
DENV NS5 RdRp Inhibitor
3'-Deoxy-GTP (3′-Deoxyguanosine 5′-triphosphate) is a nucleotide analog that serves as a potent inhibitor of DENV NS5 RNA-dependent RNA polymerase (RdRp). Functioning as a chain terminator, it effectively suppresses RNA synthesis, making it a valuable tool in virology research. With an IC50 of 0.02 μM against DENV NS5 RdRp, this compound is crucial for studies focusing on antiviral mechanisms and the development of therapeutic strategies targeting dengue virus infections. -
BTK/MNK Dual Inhibitor
QL-X-138 is a selective dual inhibitor of Bruton's tyrosine kinase (BTK) and MAPK-interacting kinase (MNK), demonstrating potent covalent binding to BTK and non-covalent binding to MNK. It exhibits IC50 values of 9.4 nM for BTK, and 107.4 nM and 26 nM for MNK1 and MNK2, respectively. Additionally, QL-X-138 displays antiviral activity against dengue virus serotype 2, with an IC50 of 3.5 μM. This compound is valuable for research involving B-cell malignancies and related therapeutic investigations. -
NS3-NS4B interaction inhibitor
(+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor that targets the NS3–NS4B protein interaction. It demonstrates nanomolar to picomolar antiviral activity across a panel of 21 clinical dengue virus isolates. With a favorable pharmacokinetic profile, (+)-JNJ-A07 exhibits exceptional efficacy in mouse models of dengue virus infection, making it a strong candidate for antiviral research and therapeutic development. -
GPI/NS2B-NS3/CK1ε Inhibitor
Rhodiolin is a flavonoid that acts as a GPI (glucose 6-phosphate isomerase) and NS2B-NS3 protease inhibitor, with significant implications for cancer and viral research. It demonstrates the ability to inhibit glycolysis in papillary thyroid cancer, leading to suppressed PI3K/AKT/mTOR signaling and induced apoptosis. Additionally, Rhodiolin disrupts dengue viral replication through its action on the NS2B-NS3 protease. With its potential to inhibit CK1ε kinase, it serves as a valuable candidate for developing anticancer strategies and investigating anti-tumor and antiviral mechanisms. -
Tau Aggregation Inhibitor
Nimbin is a potent tau aggregation inhibitor derived from the limonoid class of compounds found in Azadirachta. It is shown to enhance cell viability while effectively inhibiting the envelope protein of the dengue virus. Additionally, Nimbin exhibits a range of biological activities, including anti-inflammatory, antifungal, antihistamine, antiseptic, antioxidant, anticancer, and antiviral properties. This diverse activity profile makes Nimbin a valuable reagent for research in neurodegenerative diseases and viral infections. -
Dengue Protease Inhibitor
Carbonic anhydrase inhibitor 16 is a potent dengue protease inhibitor that targets human carbonic anhydrases I and II, exhibiting inhibitory constants (Ki) of 28.5 nM and 2.2 nM, respectively. This compound demonstrates significant biological activity in hindering dengue virus replication by disrupting protease function. It may be utilized in research applications aimed at elucidating mechanisms of dengue virus pathogenesis and developing antiviral therapeutics. -
Macropinocytosis inhibitor
Virapinib is a potent macropinocytosis inhibitor that demonstrates significant antiviral activity. It effectively inhibits viral entry of a broad range of viruses, including SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, while also enhancing Dengue Virus infection. By obstructing macropinocytosis, Virapinib reduces syncytium formation in SARS-CoV-2-infected cells and hinders the cellular entry of SARS-CoV-2 variants. This compound is valuable for research focused on viral pathogenesis and therapeutic evaluations related to COVID-19 and other viral infections. -
NS2B/NS3 Inhibitor
NS2B/NS3-IN-5 is an allosteric inhibitor targeting the NS2B/NS3 protease of Dengue Virus Serotype 2 (DENV2) and Zika Virus (ZIKV). It demonstrates effective inhibitory activity with IC50 values of 0.67 µM against ZIKV and 4.38 µM against DENV2 NS2B/NS3 proteases. This compound presents significant potential for research applications in virology, specifically in the development of antiviral therapies targeting these flavivirus proteases. -
NS2B/NS3 Inhibitor
NS2B/NS3-IN-4 is an allosteric inhibitor targeting the NS2B/NS3 protease of dengue virus serotype 2 (DENV2) and Zika virus (ZIKV). It demonstrates IC50 values of 0.69 µM for DENV2 and 1.04 µM for ZIKV proteases, highlighting its potent enzymatic inhibition. This compound serves as a valuable tool in antiviral research, particularly for elucidating mechanisms of viral replication and developing therapeutic strategies against flavivirus infections. -
NS2B/NS3 Inhibitor
NS2B/NS3-IN-6 is an allosteric inhibitor targeting the NS2B/NS3 protease of Dengue virus (DENV) and Zika virus (ZIKV). It exhibits IC50 values of 2.23 µM and 25.2 µM against ZIKV and DENV proteases, respectively. This compound is valuable for research applications focused on developing antiviral therapies and understanding the enzymatic mechanisms of flavivirus proteases. -
DENV2 Inhibitor
YKL-04-085 is a potent inhibitor of dengue virus serotype 2 (DENV2) translation, demonstrating an IC90 of 0.555 μM. This compound specifically targets viral translation mechanisms, making it a valuable tool for research on DENV2 pathogenesis and antiviral drug development. Additionally, YKL-04-085 shows no kinase activity, allowing for more targeted investigations into its antiviral efficacy. -
GAK Inhibitor
GAK Inhibitor 2 is a selective inhibitor of cyclin G-associated kinase (GAK), exhibiting a potent IC50 value of 0.024 μM. This compound demonstrates significant antiviral activity, with an effective concentration (EC50) of 1.049 μM against dengue virus (DENV). GAK Inhibitor 2 is suitable for research exploring GAK's role in viral pathogenesis and therapeutic strategies against DENV. -
Dengue Virus Inhibitor
Mosnodenvir is an orally active pan-serotype inhibitor of the dengue virus (DENV), exhibiting EC50 values between 0.057 and 11 nM across four DENV serotypes. Its primary mechanism involves inhibiting the interaction between nonstructural proteins NS3 and NS4B, which is critical for preventing the replication of viral RNA. With demonstrated picomolar to nanomolar antiviral activity in vitro, Mosnodenvir also shows antiviral efficacy in murine and non-human primate models, making it a valuable tool for research into dengue virus treatment. -
NS4B Inhibitor
NITD-688 is an orally active inhibitor targeting the NS4B protein of the dengue virus. This compound exhibits pan-serotype activity against various strains of dengue virus (DENV) and is essential for investigating the molecular mechanisms of dengue virus replication. NITD-688 serves as a valuable tool in the development of antiviral strategies and therapeutic interventions for dengue virus infections. -
Translation Elongation Inhibitor
Lactimidomycin is a glutarimide-containing compound that functions as a potent inhibitor of eukaryotic translation elongation. It demonstrates significant antiproliferative effects on various tumor cell lines and selectively disrupts protein synthesis, with an IC50 value of 37.82 nM. Additionally, Lactimidomycin exhibits strong antiviral activity against dengue virus 2 and other RNA viruses, making it a valuable reagent for cancer research and antiviral studies. -
NS2B/NS3 Inhibitor
NS2B/NS3-IN-2 is a potent inhibitor of the dengue virus (DENV) NS2B/NS3 protease, demonstrating an IC50 of 6.0 nM and a Ki of 0.66 µM. This covalent inhibitor exhibits no cytotoxicity and significantly enhances cell survival rates, making it an important tool for research in dengue virus therapeutics and antiviral development. -
Dengue Viral Inhibitor
1,8-Dihydroxy-4,5-dinitroanthraquinone is an effective inhibitor of the dengue viral serine proteinase NS2B/3. This compound demonstrates significant antiviral activity with an IC50 of 4.2 μM against viral replication, while also exhibiting proteinase inhibition with an IC50 of 432 μM. Additionally, 1,8-Dihydroxy-4,5-dinitroanthraquinone disrupts NS2B/3 cleavage in BHK-21 cells, providing a valuable tool for research into dengue virus mechanisms and potential therapeutic strategies. -
RdRp Inhibitor
HeE1-2Tyr is a pyridobenzothiazole compound that serves as an inhibitor of RNA-dependent RNA polymerases (RdRp) in flavivirus. It demonstrates significant inhibitory activity against West Nile, Dengue, and SARS-CoV-2 RdRps, with an IC50 value of 27.6 μM in vitro. HeE1-2Tyr is valuable for research investigating viral replication and potential therapeutic strategies targeting RNA polymerase activity. -
RNA Viral Inhibitor
KIN101 is a potent RNA viral inhibitor, demonstrating IC50 values of 2 µM and >5 µM against influenza virus and Dengue virus (DNV), respectively. It acts as an isoflavone agonist of IRF-3 dependent signaling, promoting the nuclear translocation of IRF-3. This compound exhibits broad-spectrum antiviral activity against various RNA viruses, making it a valuable tool for research in virology and antiviral therapeutics. -
Dengue Viru Inhibitor
SP187 is a host-targeted iminosugar that inhibits Dengue virus replication by interfering with viral glycan processing. This compound has demonstrated antiviral activity against both filovirus and influenza infections in vitro and in vivo. SP187 serves as a valuable research tool for studying dengue virus biology and developing therapeutic strategies for viral infections. -
HCV NS3 Helicase Inhibitor
ML283 is a potent inhibitor of the HCV NS3 helicase, with an IC50 value of 2.6 μM. Additionally, ML283 displays inhibitory activity against the dengue virus (DenV) ATPase, with an IC50 of 4.0 μM. This compound is valuable for research focused on hepatitis C virus and dengue virus replication mechanisms, providing a tool for the development of antiviral therapies. -
Influenza Virus Inhibitor
Glabranine is a flavonoid compound recognized for its inhibitory effects against the influenza virus. Isolated from Tephrosia species, it demonstrates significant interaction with the soluble ectodomain of the dengue virus type 2 (DENV2) E protein, suggesting potential applications in antiviral research. This compound serves as a valuable tool for investigating the mechanisms of viral inhibition and offers insights into therapeutic strategies against influenza and related viral infections. -
Dengue Virus Protease Inhibitor
SP-471 is a potent inhibitor of the dengue virus (DENV) protease, demonstrating an IC50 value of 18 μM. It effectively targets both intermolecular and intramolecular protease activities, making it a valuable tool for research on dengue virus pathogenesis and antiviral drug development. This compound is suitable for studies focused on elucidating viral protease mechanisms and testing potential therapeutic interventions. -
AChE Inhibitor
Temephos is an organophosphate insecticide that functions as an irreversible inhibitor of acetylcholinesterase (AChE). This inhibition leads to cholinergic overactivation, effectively disrupting the larval development of Aedes aegypti and Aedes albopictus, making it a valuable tool in research concerning Dengue Virus, Zika Virus, and other mosquito-borne pathogens. While exhibiting important biological activity, Temephos has been shown to cause genotoxicity, neurodevelopmental toxicity, and potential liver and reproductive system effects in mammals. Additionally, it can accumulate in adipose tissues and aquatic organisms, with its metabolism primarily occurring through oxidation and hydrolysis. Temephos serves as a critical reagent in studies of vector control and viral transmission dynamics. -
Dengue Viru Inhibitor
BP13944 is a small molecule inhibitor that targets the dengue virus (DENV) by inhibiting its NS3 protease. It demonstrates significant antiviral activity, effectively suppressing the replication of all four DENV serotypes with an EC50 value of 1.03±0.09 μM, while showing no toxicity to host cells. Notably, the presence of the E66G mutation in the NS3 protease confers resistance to BP13944. As a promising candidate for dengue virus intervention, BP13944 represents a potential therapeutic agent in the absence of effective vaccines or treatments for dengue. -
Dengue Viru Inhibitor
ST-148 is a novel small molecule compound that acts as a potent inhibitor of all four serotypes of the dengue virus. In studies using a nonlethal AG129 mouse model, ST-148 significantly decreased viremia and viral load in key organs, while also showing a tendency to reduce plasma cytokine levels. The mechanism of action involves direct interaction with the dengue virus capsid protein, indicating that ST-148 interferes with specific stages of the viral replication cycle, which may provide avenues for therapeutic development against dengue virus infections. -
DENV-1/DENV-2 Inhibitor
DENV-IN-12 is a potent inhibitor targeting Dengue Virus serotypes 1 and 2. This compound, a derivative of N-methylcytisine thio, demonstrates significant antiviral activity against DENV-2, with EC50 values ranging from 0.002 to 0.005 μM across various cell lines. DENV-IN-12 serves as a valuable tool for research applications focused on understanding dengue virus pathogenesis and developing antiviral therapeutics. -
DENV2 Inhibitor
DENV-IN-9 (Compound 5f) is a potent inhibitor of the dengue virus serotype 2 (DENV2), exhibiting an EC50 of 0.88 μM. This compound effectively curtails viral replication, making it a valuable tool for research focused on dengue virus pathology and potential antiviral therapeutic strategies. Its potency and specificity position DENV-IN-9 as a significant candidate for studies aimed at understanding DENV2 inhibition mechanisms. -
DENV2 Inhibitor
DENV-IN-8 is a selective DENV2 inhibitor that exhibits an EC50 value of 0.068 μM. This compound effectively disrupts viral replication, making it a valuable tool for research aimed at understanding dengue virus pathogenesis and developing antiviral strategies. Its high potency and specificity for DENV2 facilitate studies in virology and drug discovery. -
RdRp Domain Inhibitor
NITD-203 is an inhibitor targeting the RNA-dependent RNA polymerase (RdRp) domain. It exhibits potent inhibitory activity against all four serotypes of dengue virus (DENV), as well as yellow fever virus (YFV) and West Nile virus (WNV). This compound is valuable for research applications focusing on the development of antiviral therapies and understanding the molecular mechanisms of viral replication. -
DENV Inhibitor
DENV-IN-10 is a potent tetravalent inhibitor targeting dengue virus (DENV). It demonstrates effective suppression of DENV replication with EC50 values of 1.36, 0.87, 0.94, and 0.95 μM against DENV serotypes 1-4, respectively. This compound functions as a post-entry replication inhibitor, exhibiting specificity for primate-derived cells, making it a valuable tool for research into dengue virus biology and therapeutic intervention. -
DENV Inhibitor
SDM25N is a Dengue virus (DENV) inhibitor that targets the NS4B protein, effectively disrupting genomic RNA replication. With an EC50 of 1.9 µM, SDM25N demonstrates cell type-specific inhibition of DENV. This compound is valuable for research into DENV infection and the mechanisms of viral replication. -
Endoplasmic Reticulum α-glucosidase II (GluII) Inhibitor
ToP-DNJ is a specific inhibitor of endoplasmic reticulum α-glucosidase II (GluII), demonstrating an IC50 value of 9.0 μM. It selectively interferes with both catalytic reactions of GluII, showing enhanced activity in the initial conversion of di-glycosylated to mono-glycosylated glycans. Additionally, ToP-DNJ exhibits anti-DENV activity, making it a valuable tool for research into dengue virus infection and related glycobiology studies. -
NS4B Inhibitor
JMX0254 is a potent inhibitor of the dengue virus NS4B protein, exhibiting oral bioavailability. It displays effective antiviral activity with EC50 values of 0.78 µM, 0.16 µM, and 0.035 µM against DENV-1, DENV-2, and DENV-3, respectively. This compound is valuable for research applications focused on understanding and combating dengue virus infections. -
Influenza Viru Inhibitor
SP187 hydrochloride is a host-targeting iminosaccharide that primarily inhibits endoplasmic reticulum glucosidase, rendering it effective against filovirus infections. This compound demonstrates antiviral activity, notably against the Dengue virus, in vivo. SP187 hydrochloride is a valuable tool for researchers investigating antiviral mechanisms and developing therapeutic strategies against viral infections. -
DENV MTase Inhibitor
CNP0296775 is a potent inhibitor of dengue virus methyltransferase (DENV MTase), targeting key enzymatic processes involved in viral replication. By disrupting the activity of this enzyme, CNP0296775 shows promise in studying dengue virus pathogenesis and could serve as a valuable tool in antiviral research. Its application in preclinical studies may aid in the development of novel therapeutic strategies for dengue virus infections. -
NS2B-NS3 Inhibitor
NS2B/NS3-IN-9 is a non-competitive inhibitor targeting the NS2B-NS3 protease of Orthoflavivirus, demonstrating broad-spectrum antiviral activity. It exhibits IC50 values of 2.4 μM, 7.2 μM, and 1.9 μM against the Dengue virus DENV2, West Nile virus WNV, and Zika virus ZIKV, respectively. Additionally, NS2B/NS3-IN-9 shows cellular EC50 values of 4.1 μM for DENV2, 4.9 μM for WNV, and 5.0 μM for ZIKV, while exhibiting minimal toxicity to host cells. This compound is suitable for research applications focused on inhibiting Orthoflavivirus infections. -
NS2B·NS3 Protease Inhibitor
CN-716 dihydrochloride is a reversible covalent inhibitor targeting the NS2B·NS3 protease of flaviviruses, demonstrating significant antiviral activity. This compound effectively impedes the replication of dengue virus (DENV2), West Nile virus (WNV), and Zika virus (ZIKV), with IC50 values of 0.066 μM, 0.11 μM, and 0.25 μM, respectively. Additionally, CN-716 dihydrochloride exhibits Ki values of 0.051 μM, 0.082 μM, and 0.04 μM against the same proteases. It serves as a valuable tool for investigating the infection mechanisms associated with dengue fever, West Nile fever, and Zika virus infection. -
NS2B-NS3 Inhibitor
Ac-EVKKQR-pNA is a competitive chromogenic para-nitroanilide substrate designed to probe the NS2B-NS3 cleavage site. This reagent includes a readily hydrolyzable para-nitroanilide at the P1’ position, enhancing its reactivity. It is primarily used in studies of dengue virus type 2 and other flavivirus infections, facilitating the exploration of viral protease activity and potential therapeutic interventions.
